Skip to main content

Loading market ticker...

Zydus Wellness (NSE:ZYDUSWELL): What Did Management Reveal in Q1 FY27 Earnings Call?

Zydus Wellness (NSE:ZYDUSWELL): What Did Management Reveal in Q1 FY27 Earnings Call?

Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn More

Zydus Wellness Limited (NSE:ZYDUSWELL) filed the transcript of its Q1 FY2027 earnings conference call on 10 August 2026, pursuant to SEBI Listing Regulations 30 and 46. The call, held on 4 August 2026, disclosed consolidated net sales of Rs 14,299 million, reflecting 66.7% year-on-year growth.

Key Highlights

  • Consolidated net sales for Q1 FY27 stood at Rs 14,299 million, a year-on-year increase of 66.7%, as disclosed in the earnings call transcript.
  • EBITDA grew 55.3% year-on-year to Rs 2,417 million, with overall EBITDA margin expanding approximately 0.4% on a like-to-like basis.
  • Net profit declined 7% during the quarter; however, net profit excluding amortisation of acquired brands registered growth of 26.5%.
  • The international business, including the Comfort Click business, delivered like-to-like growth of 24.8%, while the domestic business grew 4.6%.

About the Company

Zydus Wellness Limited (NSE:ZYDUSWELL), headquartered in Ahmedabad, is a consumer health and wellness company operating in personal care, food and nutrition, and skin care segments. Key brands include Sugar Free, Complan, Glucon-D, Nycil, Everyuth, Nutralite, and RiteBite Max Protein. The company also operates the international Comfort Click business. It is listed on the NSE and BSE.

Announcement in Detail

The transcript, filed under SEBI LODR Regulations 30 and 46(2)(oa)(iii), covers the call hosted by ICICI Securities on 4 August 2026. CEO Tarun Arora, CFO Umesh Parikh, and Non-Executive Director Ganesh Nayak represented management. Within the domestic portfolio, Skin and Hair Care grew 34.5% and Food and Nutrition grew 16%, while seasonal brands declined 12%, primarily due to unseasonal rainfall in the Eastern region and North India affecting Nycil and Glucon-D.

The CFO confirmed a transition from a GBP loan to a euro-denominated loan, reducing interest costs, with the effective finance cost run rate expected to remain broadly stable subject to euro benchmark rate movements. The effective tax rate for Q1 FY27 was approximately 27%, elevated due to thin capitalisation rule disallowances in the UK, with the normalised rate expected near 25% for FY27, of which the cash component is projected at 12% to 15%.

Impact on Investors

Investors will note that the reported net profit decline of 7% is attributable partly to amortisation of acquired brands, a non-cash charge; excluding this item, net profit grew 26.5%. The filing shows the Comfort Click acquisition continues to be EPS accretive, though the higher effective tax rate in Q1 reflects a jurisdiction-specific disallowance rather than a structural change in the tax profile.

Shareholders will observe that management did not provide a specific forward revenue or margin guidance during the call, maintaining a double-digit international growth indication only. The organised channel mix, with digital commerce at 21% and modern trade at 17%, reaching a combined 38% saliency, is a disclosed operational metric investors may track over subsequent quarters.

Sector / Market Context

India's fast-moving consumer goods sector has seen sustained premiumisation trends, with organised and digital commerce channels gaining share. The Ministry of Consumer Affairs and industry bodies such as FICCI have noted a structural shift in consumer spending towards health, wellness, and convenience formats, a backdrop relevant to Zydus Wellness's portfolio positioning across nutrition, skin care, and sugar substitutes.

Unlock Premium Articles for Exclusive Insights!

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

Copyright 2026 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.